We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Agios (AGIO) Assigns Ex-Celgene Executive to CEO Position
Read MoreHide Full Article
Agios Pharmaceuticals, Inc. (AGIO - Free Report) announced that it has appointed Dr. Jacqualyn Fouse as the company’s new chief executive officer (CEO) effective Feb 1, 2019. She will succeed Dr. David Schenkein, the current CEO.
Following this shuffle, Dr. Schenkein will now join as the chairman on the directorial board of directors and also serve as a member of the science & technology committee board.
Dr. Fouse comes in with a baggage of vast experience, having led various organizations over the years. Most recently, she served as the president and chief operating officer of Celgene Corporation before quitting the house last June. She has also been a member of Agios’ board since December 2017. No wonder, this played an instrumental role in her selection for assuming the new role.
Shares of Agios have surged 41.9% so far this year, comparing favorably with the industry’s rally of 15.8%.
Notably, Dr. Schenkein held office as the company’s CEO since 2009. During his tenure, Agios evolved from a pure research organization to a fully integrated biopharmaceutical company with two approved products in its portfolio and has visibly made a strong pipeline progress.
In July 2018, the FDA approved Agios’ leukemia drug Tibsovo (ivosidenib) for treating adult patients suffering relapsed/refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH-1) mutation. A regulatory filing for the drug in the EU is expected in the fourth quarter of 2018 for the same indication.
Agios’ first commercialized drug Idhifa was approved last August for administering in adult patients with relapsed or refractory AML or R/R AML and an IDH2 mutation. Idhifa is owned by Agios’ partner Celgene while the former is entitled to receive royalties on the drug’s net sales. Idhifa is under review in the EU for the same disease.
Eagle Pharmaceuticals’ earnings estimates have moved 13.6% north for 2018 and 10.2% for 2019 over the past 60 days. The stock has gained 25.3% year to date.
Quidel’s earnings estimates have been revised 8.8% upward for 2018 and 9% for 2019 over the past 60 days. The stock has soared 72.9% so far this year.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Agios (AGIO) Assigns Ex-Celgene Executive to CEO Position
Agios Pharmaceuticals, Inc. (AGIO - Free Report) announced that it has appointed Dr. Jacqualyn Fouse as the company’s new chief executive officer (CEO) effective Feb 1, 2019. She will succeed Dr. David Schenkein, the current CEO.
Following this shuffle, Dr. Schenkein will now join as the chairman on the directorial board of directors and also serve as a member of the science & technology committee board.
Dr. Fouse comes in with a baggage of vast experience, having led various organizations over the years. Most recently, she served as the president and chief operating officer of Celgene Corporation before quitting the house last June. She has also been a member of Agios’ board since December 2017. No wonder, this played an instrumental role in her selection for assuming the new role.
Shares of Agios have surged 41.9% so far this year, comparing favorably with the industry’s rally of 15.8%.
Notably, Dr. Schenkein held office as the company’s CEO since 2009. During his tenure, Agios evolved from a pure research organization to a fully integrated biopharmaceutical company with two approved products in its portfolio and has visibly made a strong pipeline progress.
In July 2018, the FDA approved Agios’ leukemia drug Tibsovo (ivosidenib) for treating adult patients suffering relapsed/refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH-1) mutation. A regulatory filing for the drug in the EU is expected in the fourth quarter of 2018 for the same indication.
Agios’ first commercialized drug Idhifa was approved last August for administering in adult patients with relapsed or refractory AML or R/R AML and an IDH2 mutation. Idhifa is owned by Agios’ partner Celgene while the former is entitled to receive royalties on the drug’s net sales. Idhifa is under review in the EU for the same disease.
Agios Pharmaceuticals, Inc. Price and Consensus
Agios Pharmaceuticals, Inc. Price and Consensus | Agios Pharmaceuticals, Inc. Quote
Zacks Rank & Stocks to Consider
Agios currently carries a Zacks Rank #3 (Hold). Two better-ranked stocks in the healthcare sector are Eagle Pharmaceuticals, Inc. (EGRX - Free Report) and Quidel Corporation (QDEL - Free Report) , both sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Eagle Pharmaceuticals’ earnings estimates have moved 13.6% north for 2018 and 10.2% for 2019 over the past 60 days. The stock has gained 25.3% year to date.
Quidel’s earnings estimates have been revised 8.8% upward for 2018 and 9% for 2019 over the past 60 days. The stock has soared 72.9% so far this year.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>